Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the publication of results from C-SURFER,
the first Phase 31 clinical trial to investigate an all-oral,
ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in
treatment-naïve and treatment-experienced patients with advanced chronic
kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1)
infection.
Language:
English
Contact:
MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Chronic Kidney Disease | Clinical Trials | Hepatitis | Hepatitis C | Merck | Pharmaceuticals | Study | Urology & Nephrology